

1 **Long title:**
2 **Predictors of successful weaning from Venous-Arterial Extracorporeal Membrane**
3 **Oxygenation (V-A ECMO): A Systematic Review and Meta-analysis**
4

5 **Short title: Predictors of V-A ECMO weaning success**
6

7 **Authorship**

8 Dr. Henry R. Hsu (1)*

9 Dr. Praba Sekhar (2,3)*

10 Ms Jahnavi Grover (4)

11 Dr. David H. Tian (2,5)

12 Dr. Ciaran Downey (6)

13 Dr Ben Maudlin (1)

14 Dr. Chathuri Dissanayake (6)

15 A/Prof Mark Dennis (1,6)

16 *Dr Hsu and Dr Sekhar contributed to the paper equally as first authors.
17

18 **Affiliations**

19 1. The University of Sydney - School of Medicine, Sydney, New South Wales, Australia

20 2. Department of Anaesthesia and Perioperative Medicine, Westmead Hospital, Sydney,
21 Australia

22 3. The School of Public Health and Preventive Medicine, Monash University, Melbourne,
23 Victoria, Australia

24 4. School of Medicine - Western Sydney University, Sydney, New South Wales, Australia

25 5. Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia

26 6. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

27

28

29 **Correspondence**

30 Dr. Mark Dennis

31 Faculty of Medicine and Health, Sydney, Australia

32 Missenden Road, Camperdown, Sydney, NSW 2050 Australia

33 Email: mark.dennis@sydney.edu.au

34

35 **ABSTRACT**

36 **Background:**

37 Venoarterial extracorporeal membrane oxygenation (V-A ECMO) use to support patients in
38 cardiac failure is increasing. Despite this increased use, predicting successful weaning from
39 ECMO can be challenging, no uniform guidelines on weaning exist. Therefore, we completed a
40 systematic review to evaluate prognostic factors that predict successful weaning from V-A ECMO.

41

42 **Methods:**

43 Following the PRIMSA guidelines, a systematic literature search of Medline, Embase, SCOPUS
44 and CENTRAL identified original research studies of patients requiring V-A ECMO where weaning
45 was attempted. Data was collected on demographic factors and weaning protocol, biomarkers,
46 haemodynamic, echocardiographic factors for the successfully weaned (SW) and not successfully
47 weaned (NSW) groups. Two investigators reviewed studies for relevance, extracted data, and
48 assessed risk of bias using the ROBINS-I tool. The study was registered on the international
49 prospective register of systematic reviews (PROSPERO ID# CRD42022366153).

50

51 **Results:**

52 1219 records were screened, of which 20 studies were deemed sufficient to be included in the
53 statistical analysis based on pre-specified criteria. Factors associated with successful weaning
54 were higher left ventricular ejection fraction (LVEF) (MD 9.0, 95% CI 4.1 – 13.8; $p < 0.001$) and left
55 ventricular outflow tract velocity time integral (LVOT VTI) at time of weaning, (MD 1.35, 95% CI
56 0.28 – 2.40 lactate at admission (MD -2.5, 95%CI -3.8 – -1.1, $p < 0.001$), and CK-MB at admission
57 (MD -4.11, 95%CI -6.6 to -1.6, $p = 0.001$). Critical appraisal demonstrated moderate-high risk of
58 bias owing to confounding and low sample sizes.

59

60 **Conclusion:**

61 In patients on V-A ECMO support being assessed for weaning multi-parametric assessment is
62 required. Moderate-high heterogeneity and low sample sizes warrant higher-quality studies to
63 help guide decisions to wean patients from V-A ECMO.

64

65 Keywords: Extracorporeal membrane oxygenation, Extracorporeal life support, V-A-ECMO,
66 Adults, Biomarkers, Haemodynamic, Echocardiography, Weaning, Successful

67 INTRODUCTION

68 Venous-arterial (V-A) extracorporeal membrane oxygenation (ECMO) is increasingly being used (1,
69 2) in acute cardiac failure to provide end-organ perfusion whilst definitive treatment, myocardial
70 recover occurs or bridge to left ventricular assist device (LVAD) or heart transplant is completed.

71
72 Complications whilst on V-A ECMO support are common and effect mortality and increase with
73 duration of support(3). Therefore, minimising duration of V-A ECMO support, where possible, is
74 sought. However, premature withdrawal of V-A ECMO support, may result in recurrence of
75 cardiogenic shock and effect recovering organs. Minimizing complications associated with device
76 support with the potential for hemodynamic deterioration if support is prematurely discontinued
77 can be challenging.

78
79 The definition of successful V-A ECMO weaning has been proposed as when a patient survives
80 for longer than 48 hours after ECMO explantation, with more, recent definitions as those having
81 ECMO removed and not requiring further mechanical support because of recurring cardiogenic
82 shock over the following 30 days(4, 5). Depending on the definition the proportion of V-A ECMO
83 patients successfully weaned ranged between 30-75%(4-9).

84
85 A variety of clinical, haemodynamic, biochemical and echocardiographic variables have been
86 proposed and used to guide clinical improvement and readiness to wean(10). However, criteria
87 and variables have not been completely reviewed to ascertain effectiveness(11) and meta-
88 analyses as yet not completed. Therefore, we systematically reviewed a broad range of
89 biomarkers, haemodynamic, echocardiographic and scoring systems to predict successful
90 weaning from V-A ECMO.

91

92 METHODS

93 The study was conducted as previously outlined in our registered and published protocol
94 (PROSPERO ID# CRD42022366153) and in accordance with the PRISMA (Preferred Reporting
95 Items for Systematic Reviews and Meta-Analyses) guidelines(12). Ethics approval and patient
96 consent were not required.

97

98 Search strategy

99 The search strategy is detailed in Supplementary Material. A comprehensive search of three
100 electronic databases (Medline, Embase, SCOPUS and CENTRAL) was conducted in October
101 2022, which were re-run in December 2023 and March 2024 prior to final analysis and further
102 studies retrieved for inclusion. Appropriate Boolean operators were used to combine search terms
103 that included V-A ECMO, ECMO, extra-corporeal life support, weaning, decannulation and ECLS.
104 The reference lists of all included studies were also reviewed to identify any additional articles,
105 and duplicate articles were removed. Studies that were not primarily in the English language were
106 included if they were accompanied by an English translation. There were no limitations on the
107 publication period.

108

109 Study characteristics

110 Inclusion criteria allowed for randomized controlled trials, cohort studies, case series and
111 conference abstracts that (1) considered adult or paediatric populations (2) involved patients who
112 were on V-A ECMO and (3) there was an attempt to de-cannulate/wean from ECMO. Studies
113 using ECMO as a bridge to ventricular assist device or heart transplant were excluded. Case
114 series were included if >5 patients. Studies had to report associations between variables within
115 the study and weaning success. Review publications, grey literature, non-English language
116 publications, editorials, comments, letters to the editor and animal studies were excluded. Studies
117 only assessing baseline variables with weaning success were excluded.

118

119 Study Selection

120 Title and abstract screening were conducted by independent investigators (P.S. or H.H. or C.D.).
121 Likewise, full-text screening was performed by two independent investigators (P.S. or H.H. or
122 C.D.). All conflicts were resolved by a third, senior investigator (M.D.). The systematic review
123 platform Covidence (www.covidence.org; Veritas Health Innovation, Melbourne, Australia) was
124 used to facilitate the screening process. Publications found to fulfil eligibility criteria underwent
125 data extraction.

126

127 Data extraction

128 Data was extracted from studies by two independent reviewers (P.S. or H.H. or C.D. or J.G.) using
129 Microsoft Excel. Extracted variables included but not limited to patient demographics, weaning
130 protocol, successful weaning definition, weaning success, various prognostic factors including
131 biomarkers, haemodynamic, echocardiographic and scoring systems. The primary outcome was
132 weaning success defined survival post removal of mechanical circulatory support and not
133 requiring ventricular assist device or heart transplant. Meta-analysis was planned of predictors as
134 appropriate. Missing data was reported as not reported. Authors were attempted to be contacted
135 for further or missing data via email.

136

137 Evaluation of risk of bias

138 Critical appraisal of the risk of bias for individual studies was conducted using the ROBINS-I Tool
139 (Risk of Bias in Non-Randomized Studies - of Interventions)(13). Each included study was scored
140 by two independent investigators (P.S. or J.G. or H.H.). Any discrepancies between the two
141 reviewers were resolved by discussion and mutual agreement. Studies of poor-quality following
142 risk of bias assessment were not be excluded from being included in our synthesis. Where a poor-
143 quality study has contributed to a synthesized effect estimate, we explored the impact of study

144 quality by performing sensitivity analysis by removing the poor-quality study to observe the impact
145 that bias has had on the synthesized effect.

146

147 Statistical analysis

148 Meta-analysis was completed as per the Cochrane Handbook for Systematic Reviews of
149 Interventions when the outcomes were reported by two or more trials (14). Statistical analysis was
150 performed using Review Manager (version 5.3, The Cochrane Collaboration, Oxford, UK). For
151 continuous outcomes, mean, standard deviation (SD) and sample size were extracted from each
152 of the groups. Where studies reported median and ranges or interquartile range, derived mean
153 and standard deviation as described by Wan et al. were calculated. (15). Mean differences with
154 95% confidence interval (CI) were used for continuous outcomes. An inverse variance method
155 was applied for mean difference. Heterogeneity was assessed using I^2 statistics and values
156 between 50% and 90% were considered to represent substantial heterogeneity. A random effects
157 meta-analysis model and exploring heterogeneity with sensitivity and subgroup analysis were
158 applied where appropriate. Categorisation of reported risk factors of successful weaning from
159 studies that reported multivariable adjustment was completed.

160

161

162 **RESULTS**

163 Systematic search and study selection

164 The search strategy of relevant references yielded a total of 2199 references (Figure 1). After the
165 removal of 980 duplicates, the remaining 1219 references were screened by title and abstract. A
166 total of 62 publications were deemed to be eligible for full-text screening, of which 28 studies were
167 excluded with reasons. A total of 34 articles were included in the final analysis, of which 20 studies
168 were deemed sufficient to be included in the statistical analysis. Risk of bias assessment is
169 summarised in Figure 2. The remaining 14 studies examined differing prognostic predictors that

170 were not able to be meta-analysed together. The sample sizes ranged from 12 to 265 patients,
171 with a pooled sample size of 1903 patients. Twenty-six publications were retrospective cohort
172 studies, seven were prospective cohort studies, and one not recorded. Cardiogenic shock was
173 the primary indication for V-A ECMO in ten publications, myocarditis in two, cardiomyopathy in
174 two, cardiac arrest in four, pulmonary embolism in one, post cardiac surgery in two, congenital
175 heart disease in one, acute respiratory distress syndrome in one, and eleven not recorded.
176 Geographically, fourteen publications were from Asia, eight were from North America, eleven
177 were from Europe, and one was from the Middle East. A summary of the baseline characteristics
178 of included papers and clinical variables is provided in Table 1.

179

180 **Figure 1: PRISMA flow diagram illustrating the number of studies identified by the search**
181 **and the stages in which they were chosen and eliminated**

182

183 **Figure 2: Risk of bias of the included studies (ROBINS-I)**

184

185

Author	Country	Enrolment period	Type of study	Total number of patients	Successful weaned	Unsuccessful wean	Age		Male		BMI		Heart failure (co-morbidity)	Indication for V-A-ECMO (%)	Successful weaning definition	Weaning success (%)
							Success wean	Unsuccess wean	Success wean	Unsuccess wean	Success wean	Unsuccess wean				
Aissaoui 2011 (16)	France	2007–2008	Prospective cohort	38	25	13	49 ± 14	67 ± 11	25	8	NR	NR	8	CMP (47%), FM (6%), Post-cardiotomy shock (22%), Post-transplantation (10%), Other (16%)	ECMO remoV-AI and no further MCS because of recurring CS over the following 30 days	20/38=53%
Akin 2017 (29)	Netherlands	2014–2016	Prospective cohort	13	10	3	56 ± 17	41 ± 16	9	1	NR	NR	0	PE (38%), Post-cardiotomy shock (23%), CS post-AMI (15%), Myocarditis (15%), Intoxication (8%)	Successful V-A-ECMO explantation within 48 h	10/13=77%
Aksoy 2024(16)	Turkey	2010–2019	Retrospective cohort	55	27	28	2.3	1.6	19	20	NR	NR	NR	Post-op complications following congenital heart surgery, including: low cardiac output syndrome, inability to wean from bypass, ECPR.	Wean trial when adequate myocardial contraction and haemodynamically stable, initiated with flow rate to 25%	27/55 = 49%
Chen 2022 (17)	Taiwan	NR	Retrospective cohort	47	31	16	69 ± 16	39 ± 18	15	9	NR	NR	NR	NR	Weaning from ECMO and surviV-AI beyond 48 h	31/47=66%
Colombo 2019 (31)	Italy	2013–2017	Retrospective cohort	25	18	7	NR	NR	NR	NR	NR	NR	NR	CPR (71%), CS post-AMI (17%), Myocarditis (7%), PE (4%), Takotsubo (2%), Intoxication (2%)	Device remoV-AI without requirement for re-cannulation over the following 30 days	18/25=72%
Cusanno 2022 (25)	France	2016–2021	Retrospective cohort	57	36	21	46 ± 19	57 ± 17	NR	NR	26 ± 6	25 ± 7	37	Ischemic CS (35%), Refractory CA (28%), Other (37%)	NR	36/57=63%
Daftari 2010 (27)	USA	2000–2008	Retrospective cohort	27	16	11	NR	NR	NR	NR	NR	NR	27	Heart failure (100%)	NR	16/27=59%
Junton 2023(17)	USA	2016–2021	Retrospective cohort	265	140	125	59.1 ± 13.6	59.4 ± 13.2	95	100	30.8 ± 8.1	30.4 ± 7.4	75	CPR, cardiogenic shock, post cardiotomy shock	Survival to decannulation	140/265 = 53%
Finnigan 2020 (32)	United Kingdom	NR	NR	14	NR	NR	NR	NR	NR	NR	NR	NR	NR	Post cardiac surgery support (57%), Respiratory support (43%)	NR	NR
Frederiksen 2018 (26)	Denmark	NR	Retrospective cohort	29	15	14	NR	NR	NR	NR	NR	NR	NR	NR	ECMO weaning and being alive 24 h later without hemodynamic MCS	15/29 =52%
Gonzalez Martin 2021 (33)	Spain	2013–2020	Retrospective cohort	85	52	33	NR	NR	NR	NR	NR	NR	0	CS (47%), ECPR (9%), Electrical storm (9%), Post-cardiotomy CS (33%), Other (1%)	Survival>24 h after explant and no mortality from cardiogenic shock/heart failure or cardiac arrest during admission	52/85=61%
Huang 2018 (28)	Taiwan	2014–2015	Retrospective cohort	46	28	18	59 ± 16	48 ± 15	18	15	NR	NR	8	CS/Cardiac arrest post AMI (50%), Dilated cardiomyopathy (15%), VT/VF Arrest (11%), Myocarditis (8%), PE (4%)	ECMO removal and no mortality and/or MCS because of recurring CD over the following 48 h	28/46=61%
Hutchins 2023(18)	USA	2015–2021	Retrospective cohort	199	103	96	56.2 ± 14.6	53.1 ± 16.2	67	71	NR	NR	NR	Cardiogenic shock	Successful decannulation was defined as survival without relapse to mechanical circulatory support or heart transplant within 30 days	103/199 = 51.8%
Joseph 2019 (34)	USA	NR	Retrospective cohort	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Kellnar 2024 (19)	Germany	2021–2023	Prospective cohort	12	7	5	53.0 (IQR 47.0; 60.0)	58.0 (IQR 57.5; 67.0)	NR	NR	26.9 (IQR 25.2; 30.0)	24.9 (IQR 23.7; 26.9)	NR	Cardiogenic shock	Not requiring further mechanical circulatory support within 30 days	7/12= 58%
Kim 2021 (A) (24)	South Korea	2016–2018	Prospective cohort	92	64	28	60 ± 12	59 ± 12	48	21	24 ± 3	25 ± 4	NR	CS post-AMI (48%) Ischemic cardiomyopathy (48%), Other (4%)	ECMO removal and not requiring further MCS over the following 30 days	64/92=70%
Kim 2021 (B) (18)	South Korea	2016–2019	Prospective cohort	79	50	29	63 ± 13	58 ± 12	41	23	25 ± 3	25 ± 4	NR	Post-MI CMP (52%), Idiopathic dilated CMP (18%), Fulminant myocarditis (4%), Stress-induced CMP (4%)	Successful removal of V-A-ECMO and no further mechanical circulatory support in the following 30 days	50/79=63%
L'Acqua 2019 (19)	Italy	2012–2018	Retrospective cohort	98	49	49	NR	NR	NR	NR	NR	NR	NR	NR	Patient weaned from V-A ECMO	49/98 = 50%
Lee 2023(20)	South Korea	2017–2019	Retrospective cohort	55	38	17	NR	NR	NR	NR	NR	NR	NR	NR	NR	38/55=69%
Lim 2019 (35)	South Korea	2010–2018	Retrospective cohort	122	72	50	57.8 ± 15.0	NR	NR	NR	NR	NR	NR	NR	NR	72/122=59%
Matsumoto 2018 (13)	Japan	1995–2014	Retrospective cohort	37	22	15	44 ± 32	40 ± 31	13	8	21 ± 3	22 ± 4	NR	Myocarditis (100%)	ECMO removal	22/37=59%
ongkolpun 2019 (38)	Belgium	NR	Retrospective cohort	22	12	10	NR	NR	NR	NR	NR	NR	NR	CS post-AMI (64%), post-cardiotomy (14%), Myocarditis (14%), PE (8%)	ECMO removal and HD Stabilization without the need to increase the Vasopressor dose within 24 h	12/22=55%

Naruke 2010 (22)	Japan	1996–2008	Retrospective cohort	25	18	7	54 ± 14	49 ± 18	8	5	NR	NR	3	Myocarditis (52%), CS post-AMI (36%), ACHF (12%)	ECMO weaning	18/25=72%
Naruke 2012 (40)	Japan	NR	Retrospective cohort	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	V-A-ECMO weaned of without severely deteriorated cardiac output indicated by ETCO ₂ <10 mmHg or LVET<100 ms	NR
North 2018 (41)	USA	2012–2017	Retrospective cohort	60	42	18	NR	NR	NR	NR	NR	NR	NR	NR	V-A-ECMO decannulation	42/60 = 70%
Ouazani 2019 (42)	USA	NR	Prospective cohort	12	9	3	NR	NR	NR	NR	NR	NR	NR	NR	ECMO removal without requiring any further MCS	9/12=75%
Punn 2019 (23)	USA	2010–2018	Prospective cohort	63	25	38	58 ± 21	32 ± 40	16	20	NR	NR	NR	Congenital heart defect (63%), Myocarditis (15%), Idiopathic dilated cardiomyopathy (14%), Sepsis (2%), Others (6%)	wean within 48 hours of assessment and survived without ventricular assist devices or orthotopic heart transplantation	25/63=40%
Sawada 2021 (20)	Japan	2013–2017	Retrospective cohort	50	24	26	76 ± 21	64 ± 29	20	17	23 ± 6	23 ± 6	5	CS post-AMI (54%) FM (24%) CMP (10%) other heart disease (12%)	ECMO removal and survival beyond 30 days without needs for further MCS	24/50=48%
Stull 2013(21)	USA	2010–2013	Retrospective cohort	23	15	8	NR	NR	NR	NR	NR	NR	NR	ARDS (100%)	NR	15/23=65%
Sugiura 2019 (21)	Japan	2012–2016	Retrospective cohort	55	28	27	64 ± 14	68 ± 16	21	25	25 ± 4	25 ± 5	NR	CS post-AMI (100%)	ECMO removal	28/55=51%
Sugiyama 2019 (46)	Japan	2011–2018	Retrospective cohort	74	37	37	NR	NR	NR	NR	NR	NR	NR	NR	Patient survives more than 48 h after the removal of cannulas of ECMO	37/74 = 50%
V-ArodornV-Anichkul 2023 (22)	Thailand	2018–2021	Retrospective cohort	57	46	11	NR	NR	NR	NR	NR	NR	NR	Cardiogenic shock	NR	46/57=81%
Voigt 2022 (14)	Germany	2017–2020	Retrospective cohort	40	16	24	51 ± 17	60 ± 15	10	18	28 ± 6	27 ± 6	NR	Cardiac arrest (40%), Cardiogenic shock (60%)	V-A-ECMO decannulation and subsequent discharge	16/40 = 40%
Vatanabe 2023)	Japan	2010–2016	Retrospective cohort	41	17	24	70.6±13.2	68.0±14.5	12	17	NR	NR	NR	NR	Survival for more than 24 hours after V-A-ECMO withdrawal without requiring reintroduction	17/41=41%

186

187 *Table 1: Characteristics of included studies*

188

189 ACHF acute on chronic heart failure, AMI acute myocardial infarction, ARDS acute respiratory
 190 distress syndrome, CA Cardiac arrest, CMP cardiomyopathy, CPR cardiopulmonary
 191 resuscitation, CS cardiogenic shock, ECMO extracorporeal membranous oxygenation, FM
 192 fulminant myocarditis, MCS mechanical cardiac support, NR not reported, PE pulmonary
 193 embolism, VF ventricular fibrillation, VT ventricular tachycardia

194

195 Biomarkers

196 Markers of organ damage were inversely associated with weaning success – Figure 3. Lower
 197 levels of creatinine kinase (CK-MB) (MD -4.1, 95%CI -6.6 – -1.6, p=0.001; I² = 24%), lactate at
 198 admission (MD -2.5, 95%CI -3.8 – -1.1, p<0.001; I² =85%), and lower levels of alanine
 199 aminotransferase (ALT) (MD -36.7, 95%CI -65.5 – 7.9, P=0.01; I² = 0%) at the time of weaning

200 were associated with weaning success. Too few studies reported NT-ProBNP or Troponin to
201 enable analysis.

202

203 **Figure 3 Forrest plot of comparison of haemodynamic parameters on V-A ECMO**
204 **Weaning**

205

206 Haemodynamics

207 Patients with higher pulse pressure (MD 13.1, 95%CI 7.7 – 18.5, $p < 0.001$; $I^2 = 44\%$) and systolic
208 blood pressure (MD 15.7, 95%CI 5.4 – 25.9, $p < 0.001$; $I^2 = 86\%$) were associated with weaning
209 success – Figure 4.

210

211 **Figure 4 Forrest plot of comparison of laboratory parameters on V-A ECMO**

212

213 Echocardiography

214 Patients with higher left ventricular ejection fraction (LVEF) at time of weaning (MD 9.0, 95% CI
215 4.1 – 13.8; $p < 0.001$; $I^2 = 85\%$), left ventricular outflow tract velocity time integral (LVOT VTI) (MD
216 1.35, 95% CI 0.28 – 2.40, $p = 0.01$; $I^2 = 0\%$), E/Ea (MD -2.72, 95% CI -4.45 - -0.98, $p = 0.002$; $I^2 =$
217 29%) were associated with weaning success – Figure 5.

218

219 **Figure 5 Forest plot of the comparison of different echocardiographic parameters on V-A**
220 **ECMO weaning**

221

222 Multi-variable adjusted: Risk predictors

223 Thirteen studies provided multi-variable adjusted analysis to identify predictors of successful
224 weaning. Covariates tested varied widely between studies; only lack of renal failure or CRRT
225 during ECMO, and post-weaning lactate, reported by more than one study as predictors of
226 successful ECMO weaning – Table 2.

Baseline characteristics	Study
Normal RV function	Puerto(24)
No pre-existing ischemic cardiopathy	Cusanno(9)
Post PCI TIMI flow	Sugiura(25)
While on ECMO	
No CRRT	Kim(26)
No need for LV venting	Kim (26)
10% improvement of tricuspid S' during ECMO flow study	Kim(27)
Any improvement of lateral e' during ECMO flow study	Kim(27)
ECMO duration	Punn(28)
Implantation-weaning test delay < 7 days	Cusanno(9)
Echo findings on weaning	
VTI	Lim(29), Punn(28)
LV EF	Punn(28)
Corrected LV ejection time/PAWP	Sawada(30)
Tricuspid annular S'/RSVP >0.33	Kim(26)
RV EF	Huang(31)
Normal RV function	Puerto(24)
RV free wall strain	Huang(31)
RV FAC	Huang(31)
Hemodynamics	
HR on day of decannulation	Liu(32)
MAP at weaning	Lim(29)
MAP at 4hrs	Sugiura(25)
Post-test SBP > 120 mmHg	Cusanno(9)
CVP on day of decannulation	Huang(31)
Post de-cannulation	
Lactate at 12hrs	Chen(33)
Lactate at 24hrs	Sugiura(25)
Lower vasoactive-inotropic score 24hrs post cannulation	Dunton(17)
Improvement of RV systolic function > 24hrs after decannulation	Puerto(24)

227
228 Table 2. Risk factors predictive of successful ECMO weaning from multi-variable logistic
229 regression models. CRRT, continuous renal replacement therapy; CVP, central venous pressure;
230 ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; FAC, fractional area
231 change; HR, heart rate; LV, left ventricle; MAP, mean arterial pressure; PAWP, pulmonary artery
232 wedge pressure; PCI, percutaneous coronary intervention; RV, right ventricle; SBP, systolic blood
233 pressure; TIMI, Thrombolysis in Myocardial Infarction score; VTI, velocity time integral.

234

235 **Study quality**

236 A total of 34 publications were eligible for quality assessment, of which 12 publications were of
237 poor quality, i.e. 'critical' risk of bias (Figure 2). Many studies did not provide detailed protocols,
238 limiting methodological assessment, appraisal of the confounding effect of intervention and bias
239 in selection of participants into the study.

240

241 **DISCUSSION**

242 In this systematic review of predictors of V-A ECMO weaning success 34 predominantly small
243 observational, studies were identified. On pooled analysis, lower levels of biochemical markers of
244 end-organ perfusion or injury (lactate, CK-MB and ALT), haemodynamic (pulse pressure and
245 systolic blood pressure) and echocardiographic indicators of myocardial function (LVEF, LVOT
246 VTI, E/Ea) were associated with successful weaning from V-A ECMO.

247

248 To our knowledge this review is only the second to systematically assess predictors of V-A ECMO
249 wean success. The first, in adult patients with specifically cardiogenic shock or cardiac arrest
250 identified similar results to our review, with lower creatine kinase and lactate levels, and higher
251 LVEF being predictors for successful weaning from V-A-ECMO (10) Other, non-systematic,
252 reviews have reported also reported lower creatine kinase and lactate levels, and higher LVEF
253 and LVOT VTI being predictors for successful weaning from V-A-ECMO (34). Several other V-
254 variables used in clinical practice (9) i.e. Troponin, NT-ProBNP, RV to PA coupling indices were
255 not identified owing to limited numbers of studies and patients reported with these.

256

257 Despite significant heterogeneity, small sample sizes and a significant risk of bias, there are some
258 conclusions that can be drawn from this review and the available literature. First, determination
259 of likely weaning success, should consider multiple variables and not be focussed on one

260 individual predictor. Factors associated with success (or failure), were present across clinical,
261 biochemical, haemodynamic and echocardiographic parameters and clinicians should avoid
262 relying on one variable over the complete picture of the patient. Second, initial severity of illness
263 (e.g. lactate), markers of end-organ perfusion, and then recovery of such are important
264 considerations in attempting to wean (25, 35, 36). Further, absolute cut offs for specific variables
265 e.g. LVEF or LVOT VTI to predict weaning success vary between studies, are based empirical
266 clinical weaning protocols (34, 37) and therefore cannot yet be elucidated. Overall restitution and
267 improvement of the overall clinical state of the patient as well as cardiac function is likely key to
268 successful weaning rather than a specific variable or level of a variable.

269
270 Formal weaning or “ramp” studies that assess haemodynamic and echocardiographic changes to
271 alterations to ECMO flows protocols are recommended (38) but as yet no standardised protocols
272 exist, are only variably reported in ECMO trials, and are not formally assessed in this systematic
273 review. However, they are critical tools to assess the response of cardiac function to reduction,
274 and then removal, of mechanical circulatory support (9, 39). Future prospective clinical trials
275 should publish weaning strategies and protocols to enable further assessment and comparison
276 of strategies.

277
278 **Limitations**

279 Our review is limited by the lack of large high-quality trial, with all included studies consisting of
280 observational studies with small sample sizes and these small trials were used to investigate
281 widely varying interventions amongst this population group, often performed without covariate
282 adjustment. However, we completed a comprehensive review of the literature including all
283 commonly used variables for V-A ECMO weaning. Micro-circulation indices were not assessed
284 but are not in uniform clinical practice which was our focus.

285

286 **CONCLUSIONS**

287 In patients requiring V-A ECMO support, multiple biochemical, haemodynamic and
288 echocardiographic parameters of recovery, rather than a single variable should be used to guide
289 appropriateness for weaning. Further larger studies are required to determine optimal weaning
290 strategies.

291

292 AUTHOR CONTRIBUTIONS

293 Praba Sekhar, Henry Hsu and Mark Dennis conceived and designed the project. Praba Sekhar,
294 Henry Hsu, Ciaran Downey and Jahnvi Grover conducted the systematic review with guidance
295 from Mark Dennis. Praba Sekhar, Jahnvi Grover and Mark Dennis drafted the manuscript.
296 Chathuri Dissanayake and Ben Maudlin provided critical clinical input and advice with the
297 manuscript. All authors read, edited, and approved the final manuscript prior to submission.

298

299 ACKNOWLEDGMENTS

300 Although this project received no specific funding, one author is currently supported by funding
301 from the National Heart Foundation of Australia and The University of Sydney (M.D.).

302

303 CONFLICT OF INTEREST

304 None of the authors has any conflict of interest to disclose.

305

306 ORCID

307 Praba Sekhar 0000-0003-2495-6739

308 Henry Hsu 0009-0001-8733-1309

309 David Tian 0000-0002-5213-9499

310 Mark Dennis 0000-0002-1281-1324

311 **References**

312

313 1. Schrage B, Becher PM, Gossling A, Savarese G, Dabboura S, Yan I, et al. Temporal
314 trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic
315 shock. *ESC Heart Fail.* 2021;8(2):1295-303.

316 2. Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, et al.
317 Management of cardiogenic shock complicating myocardial infarction. *Intensive Care Med.*
318 2018;44(6):760-73.

319 3. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis
320 of complications and mortality of extracorporeal membrane oxygenation. *Crit Care Resusc.*
321 2013;15(3):172-8.

322 4. Chen YS, Chao A, Yu HY, Ko WJ, Wu IH, Chen RJ, et al. Analysis and results of prolonged
323 resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. *J Am
324 Coll Cardiol.* 2003;41(2):197-203.

325 5. Chang WW, Tsai FC, Tsai TY, Chang CH, Jenq CC, Chang MY, et al. Predictors of
326 mortality in patients successfully weaned from extracorporeal membrane oxygenation. *PLoS One.*
327 2012;7(8):e42687.

328 6. Cavarocchi NC, Pitcher HT, Yang Q, Karbowski P, Miessau J, Hastings HM, et al.
329 Weaning of extracorporeal membrane oxygenation using continuous hemodynamic
330 transesophageal echocardiography. *J Thorac Cardiovasc Surg.* 2013;146(6):1474-9.

331 7. Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning
332 from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a
333 national inpatient database in Japan. *Crit Care.* 2016;20:80.

334 8. Pappalardo F, Pieri M, Arnaez Corada B, Ajello S, Melisurgo G, De Bonis M, et al. Timing
335 and Strategy for Weaning From Venous Arterial ECMO are Complex Issues. *J Cardiothorac Vasc
336 Anesth.* 2015;29(4):906-11.

- 337 9. Cusanno A, Aissaoui N, Minville V, Porterie J, Biendel C, Volle K, et al. Predictors of
338 weaning failure in case of VA ECMO implantation. *Sci Rep.* 2022;12(1):13842.
- 339 10. Charbonneau F, Chahinian K, Bebawi E, Lavigueur O, Levesque E, Lamarche Y, et al.
340 Parameters associated with successful weaning of veno-arterial extracorporeal membrane
341 oxygenation: a systematic review. *Crit Care.* 2022;26(1):375.
- 342 11. Lusebrink E, Stremmel C, Stark K, Joskowiak D, Czermak T, Born F, et al. Update on
343 Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation. *J Clin Med.* 2020;9(4).
- 344 12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
345 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Int J Surg.*
346 2021;88:105906.
- 347 13. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al.
348 ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.*
349 2016;355:i4919.
- 350 14. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance
351 for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews
352 of Interventions. *Cochrane Database Syst Rev.* 2019;10(10):ED000142.
- 353 15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from
354 the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* 2014;14:135.
- 355 16. Aksoy T, Arslan AH, Ugur M, Ustunsoy H. Lactate and Lactate Clearance Are Predictive
356 Factors for Mortality in Patients with Extracorporeal Membrane Oxygenation. *Braz J Cardiovasc*
357 *Surg.* 2024;39(2):e20230091.
- 358 17. Dunton K, Weeks PA, Gulbis B, Jumean M, Kumar S, Janowiak L, et al. Evaluation of
359 Vasoactive-Inotropic Score and Survival to Decannulation in Adult Patients on Venoarterial
360 Extracorporeal Life Support: An Observational Cohort Study. *ASAIO J.* 2023;69(9):873-8.
- 361 18. Hutchins E RA, Feng J, Chandra N, Hsu JJ, Bui A. Abstract 13293: Predicting Successful
362 ECMO Decannulation - A Novel Machine Learning Approach. *American Heart Association*2023.

- 363 19. Kellnar A, Naumann D, Scherer C, Lusebrink E, Joskowiak D, Peterss S, et al. Aortic arch
364 blood flow measurements as a predictor of successful ECMO weaning in cardiogenic shock.
365 Heliyon. 2024;10(5):e26773.
- 366 20. Lee J LS, Joo S, Park Y, et al. Abstract: Pulse pressure as a potential predictive factor for
367 successful weaning in patients supported by Venoaerterial Extracorporeal Membrane Oxygenation
368 without Left Ventricular Venting. ASAIO J. 2023;69:17.
- 369 21. Stull C BM, Pitcher H, Hirose H, Guarav K, Cavarocchi N. . Predictors of a successful
370 wean from extracorporeal membrane oxygenation (ECMO) for ARDS. Crit Care Med. 2013;41.
- 371 22. Varodomvanichkul C, Puwatnuttasit, P, Ariyachaipanich, A. et al. . LEFT ATRIAL STRAIN
372 FOR PREDICTING SUCCESSFUL EXTRA-CORPOREAL MEMBRANE OXYGENATOR
373 WEANING FROM CARDIOGENIC SHOCK. JACC. 2023;81:686.
- 374 23. Watanabe M AY, Hasegawas S, Hamada K, Tsukamoto K, Saito T, Furuya R, Komatsu
375 T, Mori F. Clinical factors associated with successful venoaerterial extracorporeal membrane
376 oxygenation weaning: A single-center retrospective cohort study. Critical Care and Shock.
377 2023;26:115-24.
- 378 24. Puerto E, Tavazzi G, Gambaro A, Cirillo C, Pecoraro A, Martin-Asenjo R, et al. Interaction
379 between VA-ECMO and the right ventricle. Hellenic J Cardiol. 2022;68:17-24.
- 380 25. Sugiura A, Abe R, Nakayama T, Hattori N, Fujimoto Y, Himi T, et al. Predictors of
381 Successful Weaning From Ven-Arterial Extracorporeal Membrane Oxygenation After Coronary
382 Revascularization for Acute Myocardial Infarction Complicated by Cardiac Arrest: A Retrospective
383 Multicenter Study. Shock. 2019;51(6):690-7.
- 384 26. Kim D, Park Y, Choi KH, Park TK, Lee JM, Cho YH, et al. Prognostic Implication of RV
385 Coupling to Pulmonary Circulation for Successful Weaning From Extracorporeal Membrane
386 Oxygenation. JACC Cardiovasc Imaging. 2021;14(8):1523-31.

- 387 27. Kim D, Jang WJ, Park TK, Cho YH, Choi JO, Jeon ES, et al. Echocardiographic Predictors
388 of Successful Extracorporeal Membrane Oxygenation Weaning After Refractory Cardiogenic
389 Shock. *J Am Soc Echocardiogr.* 2021;34(4):414-22 e4.
- 390 28. Punn R, Falkensammer CB, Blinder JJ, Fifer CG, Thorsson T, Perens G, et al.
391 Hemodynamic and Echocardiographic Predictors of Mortality in Pediatric Patients on Venoarterial
392 Extracorporeal Membrane Oxygenation: A Multicenter Investigation. *J Am Soc Echocardiogr.*
393 2023;36(2):233-41.
- 394 29. Lim YJ JJ. Predictors of successful weaning from veno-arterial extracorporeal membrane
395 oxygenation support. *Perfus Ger.,* 2019;34:88-9.
- 396 30. Sawada K, Kawakami S, Murata S, Nishimura K, Tahara Y, Hosoda H, et al. Predicting
397 Parameters for Successful Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation
398 in Cardiogenic Shock. *ESC Heart Fail.* 2021;8(1):471-80.
- 399 31. Huang KC, Lin LY, Chen YS, Lai CH, Hwang JJ, Lin LC. Three-Dimensional
400 Echocardiography-Derived Right Ventricular Ejection Fraction Correlates with Success of
401 Decannulation and Prognosis in Patients Stabilized by Venoarterial Extracorporeal Life Support.
402 *J Am Soc Echocardiogr.* 2018;31(2):169-79.
- 403 32. Liu SF HC, Lee CK, Kao PHL. . Clinical Predictors of Successful Weaning VA-ECMO. *J*
404 *Am Coll Cardiol.* 2022:S29-30.
- 405 33. Chen TY CC, Hsu JY, Sheu JJ, Kuo HC, Hsu MH, et al. . Comparison of the predictive
406 ability of lactate and central venous blood gas in pediatric venoarterial mode extracorporeal
407 membrane oxygenation outcome. *Pediatr Neonatol.* 2022;63(5):474-83.
- 408 34. Brahmhatt DH, Daly AL, Luk AC, Fan E, Billia F. Liberation From Venoarterial
409 Extracorporeal Membrane Oxygenation: A Review. *Circ Heart Fail.* 2021;14(7):e007679.
- 410 35. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable clinical
411 outcome in patients with cardiogenic shock due to fulminant myocarditis supported by
412 percutaneous extracorporeal membrane oxygenation. *Eur Heart J.* 2005;26(20):2185-92.

- 413 36. North M, Eckman P, Samara M, Chavez I, Schmidt C, Garberich R, et al. Peak troponin
414 predicts successful weaning from VA ECMO in patients with acute myocardial infarction
415 complicated by cardiogenic shock. *Int J Artif Organs*. 2022;45(1):68-74.
- 416 37. Ortuno S, Delmas C, Diehl JL, Bailleul C, Lancelot A, Naili M, et al. Weaning from veno-
417 arterial extra-corporeal membrane oxygenation: which strategy to use? *Ann Cardiothorac Surg*.
418 2019;8(1):E1-E8.
- 419 38. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO Interim
420 Guidelines for Venoaerterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients.
421 *ASAIO J*. 2021;67(8):827-44.
- 422 39. Aissaoui N, Caudron J, Leprince P, Fagon JY, Lebreton G, Combes A, et al. Right-left
423 ventricular interdependence: a promising predictor of successful extracorporeal membrane
424 oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. *Intensive Care*
425 *Med*. 2017;43(4):592-4.
- 426




Figure 1 PRISMA Flow

	Risk of bias domains							Overall
	D1	D2	D3	D4	D5	D6	D7	
Aissaoui 2011	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Akin 2017	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Aksoy 2024	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊗
Chen 2022	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Colombo 2019	⊖	⊖	⊖	⊕	⊗	⊕	⊗	⊗
Cusanno 2022	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Daftari 2010	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Dunton 2023	⊕	⊖	⊗	⊕	⊕	⊕	⊕	⊖
Finnigan 2020	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Frederiksen 2018	⊗	⊗	⊗	⊖	⊖	⊗	⊖	⊗
Gonzalez Martin 2021	⊗	⊗	⊗	⊕	⊗	⊗	⊗	⊗
Huang 2018	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Hutchins 2023	?	⊗	⊗	?	⊕	⊕	⊕	⊗
Joseph 2019	⊗	⊗	⊗	⊗	⊕	⊗	⊕	⊗
Kellnar 2024	⊕	⊖	⊗	⊕	⊕	⊕	⊕	⊖
Kim 2021 (A)	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Kim 2021 (B)	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
L'Acqua 2019	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Lee 2023	?	⊗	⊗	?	?	⊕	?	⊗
Lim 2019	⊗	⊗	⊗	⊗	⊕	⊗	⊖	⊗
Matsumoto 2018	⊗	⊗	⊗	⊗	⊕	⊗	⊕	⊗
Mongkolpun 2019	⊗	⊗	⊗	⊕	⊕	⊕	⊗	⊗
Naruke 2010	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Naruke 2012	⊗	⊗	⊗	⊕	⊕	⊕	⊗	⊗
North 2018	⊗	⊗	⊗	⊗	⊕	⊕	⊕	⊗
Ouazani 2019	⊗	⊗	⊗	⊗	⊕	⊗	⊗	⊗
Punn 2019	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Sawada 2021	⊗	⊗	⊗	⊗	⊖	⊗	⊗	⊗
Stull 2013	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Sugiura 2019	⊗	⊗	⊗	⊗	⊕	⊕	⊕	⊖
Sugiyama 2019	⊗	⊗	⊗	⊕	⊕	⊗	⊗	⊗
Varodomvanichkul 2023	?	⊗	⊗	?	⊕	⊕	?	⊗
Voigt 2022	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊖
Watanabe 2023	⊗	⊗	⊗	⊕	⊕	⊕	⊕	⊗

Domains:
D1: Bias due to confounding.
D2: Bias due to selection of participants.
D3: Bias in classification of interventions.
D4: Bias due to deviations from intended interventions.
D5: Bias due to missing data.
D6: Bias in measurement of outcomes.
D7: Bias in selection of the reported result.


Judgement
⊗ Critical
⊗ Serious
⊖ Moderate
⊕ Low
? No information

Figure 2 Robins Risk of Bias

Heart Rate

Study or Subgroup	Successfully Weaned			Not Successfully Weaned			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Naruke 2010	106	44	18	118	57	7	2.0%	-12.00 [-58.86, 34.86]	2010
Aissaoui 2011	95	16	20	115	19	13	17.1%	-20.00 [-32.48, -7.52]	2011
Matsumoto 2018	106.036	37.07	22	98	37.07	15	6.6%	8.04 [-16.29, 32.36]	2018
Punn 2019	121.2	26.8	25	125.7	26	38	15.7%	-4.50 [-17.87, 8.87]	2019
Sawada 2021	82	17.77	24	84	10.37	26	25.3%	-2.00 [-10.15, 6.15]	2021
Hutchins 2023	91.6	17.4	103	91	16	96	33.3%	0.60 [-4.04, 5.24]	2023
Total (95% CI)			212			195	100.0%	-4.14 [-10.99, 2.71]	


Heterogeneity: $\tau^2 = 31.10$; $\chi^2 = 10.15$, $df = 5$ ($P = 0.07$); $I^2 = 51\%$
 Test for overall effect: $Z = 1.18$ ($P = 0.24$)



Systolic Blood Pressure (mmHg)

Study or Subgroup	Successfully Weaned			Not Successfully Weaned			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Naruke 2010	84	31	18	85	4	7	12.1%	-1.00 [-15.62, 13.62]	2010
Matsumoto 2018	84	11.85185185	22	86	17.77777778	15	13.9%	-2.00 [-12.27, 8.27]	2018
Kim 2021 (A) JASE	100.3	10.3	64	97.3	15.4	28	15.2%	3.00 [-3.24, 9.24]	2021
Sawada 2021	114	25.18518519	24	100	25.92592593	26	12.3%	14.00 [-0.17, 28.17]	2021
Watanabe 2023	122.5	24.5	17	79.1	41.9	24	9.8%	43.40 [22.99, 63.81]	2023
Hutchins 2023	116	21.6	103	93.4	22.3	96	15.3%	22.60 [16.49, 28.71]	2023
Lee 2023	109.4	12.3	38	81.6	17.2	17	14.3%	27.80 [18.74, 36.86]	2023
Kellnar 2024	111.7786	16.5338	7	80.9155	29.6661	5	7.1%	30.86 [2.12, 59.61]	2024
Total (95% CI)			293			218	100.0%	15.65 [5.44, 25.86]	

Heterogeneity: $\tau^2 = 168.11$; $\chi^2 = 51.12$, $df = 7$ ($P < 0.00001$); $I^2 = 86\%$
 Test for overall effect: $Z = 3.01$ ($P = 0.003$)



Pulse Pressure

Study or Subgroup	Successfully Weaned			Not Successfully Weaned			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Aissaoui 2011	52	12	38	39	19	13	15.5%	13.00 [1.99, 24.01]	2011
Punn 2019	33.6	14.6	25	26.6	13.7	38	24.3%	7.00 [-0.19, 14.19]	2019
Sawada 2021	50	30.37037037	24	45	14.81481481	26	11.8%	5.00 [-8.42, 18.42]	2021
Lee 2023	32.8	8.1	38	18.4	8.7	17	31.5%	14.40 [9.53, 19.27]	2023
Watanabe 2023	60.1	17.6	17	35.2	21	24	14.0%	24.90 [13.04, 36.76]	2023
Kellnar 2024	50.6221	21.1265	7	24.3595	30.6717	5	2.9%	26.26 [-4.85, 57.37]	2024
Total (95% CI)			149			123	100.0%	13.09 [7.65, 18.53]	

Heterogeneity: $\tau^2 = 18.29$; $\chi^2 = 8.92$, $df = 5$ ($P = 0.11$); $I^2 = 44\%$
 Test for overall effect: $Z = 4.71$ ($P < 0.00001$)






Figure 3


Lactate (Initial)




CK-MB Max (IU/L)



BUN



pH



ALT (IU/L)






Figure 4


2.7 Fractional Shortening




2.9 TAPSE



1.10 LVOT VTI



2.6 E/Ea



1.4 LVEF




Figure 5